Introduction
============

Asthma is a common disease that is characterized by reversible airflow obstruction, airway hyperresponsiveness (AHR), airway inflammation, airway remodeling, mucus hypersecretion and subepithelial fibrosis ([@b1-ijmm-42-04-1998],[@b2-ijmm-42-04-1998]). It is a heterogeneous syndrome affected by several factors, including the environment, genetic background, and infection ([@b3-ijmm-42-04-1998]). Multiple cell types and cellular components are known to be involved in the pathophysiological processes of asthma. One important link in the pathogenesis of asthma is airway remodeling caused by recurrent injury and repair processes initiated by chronic inflammation ([@b4-ijmm-42-04-1998]). Changes in the morphology and function of airway epithelial cells are key to airway remodeling. This remodeling is considered to be the pathological basis for irreversible AHR and airway obstruction ([@b5-ijmm-42-04-1998]). During airway remodeling the number of goblet cells increases, resulting in increased mucus secretion, which can cause airway obstruction and lead to asthma-related mortality.

Repeated chronic inflammation in the asthmatic airway induces epithelial cells to transdifferentiate into myofibroblasts. This is an example of epithelial-mesenchymal transition (EMT). EMT may be involved in the process of airway remodeling and subepithelial fibrosis in asthma ([@b6-ijmm-42-04-1998]) and may be a possible mechanism of airway inflammation ([@b7-ijmm-42-04-1998]). Persistent EMT causes detrimental changes in pulmonary function ([@b8-ijmm-42-04-1998]). Furthermore, EMT decreases the sensitivity of airway epithelial cells to drug treatments and thus decreases the therapeutic efficacy of glucocorticoids in patients with severe asthma ([@b9-ijmm-42-04-1998]). Abnormal EMT is now considered to be the central event in asthma pathophysiology ([@b10-ijmm-42-04-1998]). EMT is a current focus of investigations of the mechanisms underlying airway remodeling in asthma. A variety of proteins are important in EMT, including E-cadherin and vimentin, which represent epithelial and mesothelial features, respectively. The decreased expression of E-cadherin, the increased expression of vimentin, and the transition from epithelial to mesenchymal cell morphology are important manifestations of the EMT process. However, the molecular mechanisms underlying these effects remain to be fully elucidated. No effective treatments for asthma-related airway remodeling are available ([@b11-ijmm-42-04-1998]).

Transforming growth factor β1 (TGFβ1) is an important cytokine involved in airway remodeling that mediates tissue inflammation in asthma. The mechanisms underlying the effects of TGFβ1 on asthma remain to be fully elucidated. Therefore, it is hypothesized that TGFβ1-induced EMT may be involved in the processes of airway inflammation and airway remodeling. Nuclear factor-κB (NF-κB) is an important transcriptional factor in EMT and in the epithelial cell inflammation of asthma ([@b9-ijmm-42-04-1998]). TGFβ-induced EMT is driven by NF-κB-dependent cell signaling ([@b12-ijmm-42-04-1998]). The persistent activation of NF-κB has been observed in allergic airway inflammation ([@b13-ijmm-42-04-1998]). Therefore, NF-κB has emerged as a vital therapeutic molecular target, and the inhibition of NF-κB activity may offer potential as a method to manage asthma.

Several factors are involved in regulating the expression and activity of NF-κB, providing several targets for the pharmacological inhibition of NF-κB. One inhibitor target is inhibitor of NF-κB (IκB) kinase (IKK), a kinase complex that phosphorylates IκB, the inhibitory subunit of the NF-κB complex, thereby releasing IκB and activating NF-κB. The IKK/NF-κB pathway is important in regulating inflammation. IKKβ is particularly important as a major upstream regulator of NF-κB activity, with an important role in the immune response and inflammatory reactions ([@b14-ijmm-42-04-1998]). Inhibitors of IKKβ, including BMS-345541 \[(2′-aminoethyl)amino-1,8-dimethy limidazo(1,2-a) quinoxaline\], have certain pharmacokinetic characteristics, including 100% oral bioavailability and an intravenous half-life of 2.2 h, which makes them particularly well suited for use in investigating the utility of IKK inhibitors in disease models ([@b15-ijmm-42-04-1998]). In various cell and animal models of several diseases, BMS-345541 is key in EMT and suppresses inflammatory responses by inhibiting the activation of NF-κB ([@b16-ijmm-42-04-1998]-[@b18-ijmm-42-04-1998]). These results indicate that BMS-345541 may have potent anti-inflammatory activity in the context of asthma. However, whether BMS-345541 can be used to inhibit asthma-induced airway inflammation, airway remodeling and the EMT observed in asthma, and the exact therapeutic mechanisms of BMS-345541 in asthma treatment remain to be fully elucidated.

Therefore, to provide novel ideas and methods for the clinical treatment of asthma and to investigate the mechanisms of asthma, it was hypothesized that the secretion of TGFβ1 may result in EMT, and the role of BMS-345541 on airway inflammation, airway remodeling and potentially in the regulation of EMT marker protein expression were investigated in an ovalbumin (OVA)-induced asthma model in mice. If BMS-345541 inhibits asthma phenotypes in the OVA mouse model, as expected, it is likely to be an important tool in the elucidation of the roles of TGFβ1, EMT and NF-κB in asthma pathophysiology and in the identification of targets for novel drug therapies.

Materials and methods
=====================

Animals
-------

A total of 32 female BALB/c mice aged 6-8 weeks and weighing 25±3 g were maintained in the Laboratory Animal Science Centre of Nanchang University (Nanchang, China). All the mice were housed under specific pathogen-free laboratory conditions in a 12 h light/dark cycle at a temperature of 20±5°C with 50±10% humidity. Mice had *ad libitum* access to food and water. Care was taken to alleviate any pain and suffering of the mice. All experiments were performed according to institutional regulations, and all procedures performed in the present study were approved by the Ethics Commission of Jiangxi People\'s Hospital (Nanchang, China).

Reagents
--------

The reagents used were as follows: OVA (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany), acetylcholine chloride (Ach; Sigma-Aldrich; Merck KGaA), phosphate-buffered saline (PBS; Sigma-Aldrich; Merck KGaA), sodium pentobarbital (Sinopharm Chemical Reagent Co., Ltd., Shanghai, China), BMS-345541 (Abcam, Cambridge, MA, USA), E-cadherin antibody (cat. no. ab76055; Abcam), vimentin antibody (cat. no. ab92547, Abcam), β-actin antibody (cat. no. ab179467; Abcam), glyceraldehyde 3-phosphate dehydrogenase (GADPH; Sigma-Aldrich; Merck KGaA), dimethyl sulfoxide (DMSO; Sigma-Aldrich; Merck KGaA), diaminobenzidine (DAB; Santa Cruz Biotechnology, Inc., Dallas, TX, USA), an enzyme-linked immunosorbent assay (ELISA) kit (Bio-Rad Laboratories, Inc., Hercules, CA, USA), Pierce Enhanced Chemiluminescence (ECL) western blot substrate (Thermo Fisher Scientific, Inc., Waltham, MA, USA), a reverse transcription kit (Promega Corporation, Madison, WI, USA), a quantitative polymerase chain reaction (qPCR) kit (TransStart Green; Beijing Transgen Biotech Co., Ltd., Beijing, China), a bicinchoninic acid (BCA) protein assay kit and radioimmunoprecipitation assay (RIPA) lysis buffer (Beijing ComWin Biotech Co., Ltd., Beijing, China). The qPCR primers were designed and synthesized by Nanjing Kingsy Biotechnology (Nanjing, China).

Asthma sensitization, challenge and treatment protocol
------------------------------------------------------

The 32 mice were divided into four groups of eight mice: Control, OVA, OVA + DMSO, and OVA + BMS-345541 groups. First, eight mice were randomly selected from the 32 mice as the normal control group. The remaining 24 mice were then selected to be sensitized and challenged with OVA. The mice were sensitized with intraperitoneal (i.p.) injections of 10 µg of OVA emulsified in aluminium hydroxide in a total volume of 0.2 ml on days 0, 7 and 14. Between days 21 and 28, they were challenged by aerosol exposure to 5% OVA for 30 min daily for 7 days. The control group mice were treated with PBS for sensitization and stimulation using the same protocol.

Prior to OVA challenge, the 24 sensitized mice were equally divided into three groups of eight mice: OVA group, OVA + DMSO group and OVA + BMS-345541 group. The OVA + BMS-345541 group comprised mice treated with BMS-345541. The BMS-345541 was dissolved in 1% DMSO, and the resulting solution was diluted with sterile water to a final concentration of 10 µg/µl. The OVA + DMSO group was the DMSO vehicle control group. BMS-345541 (50 mg/kg) or vehicle (20 *µ*l DMSO in a total of 200 *µ*l saline, without BMS-345541) was administered to the mice by oral gavage using a feeding needle (18 gauge, 5 cm) for 7 days ([@b19-ijmm-42-04-1998]). No such intervention was performed in the OVA group mice. The detailed experimental protocol is shown in [Fig. 1](#f1-ijmm-42-04-1998){ref-type="fig"}.

Evaluation of asthma symptom severity, and measurement of airway responsiveness
-------------------------------------------------------------------------------

A symptom assessment of asthma in mice was performed with regard to specific criteria, as previously described ([@b20-ijmm-42-04-1998]). The asthma symptoms were observed in 15 min during inhaled OVA. Airway responsiveness to Ach was measured with a whole-body and invasive plethysmography (Buxco Electronics, Inc., Troy, NY, USA) and analyzed as previously described ([@b21-ijmm-42-04-1998]). Lung resistance (RL) was measured to assess the change in AHR. At 24 h following the final challenge, all mice were weighed and anesthetized with 2% sodium pentobarbital (30 mg/kg) via i.p. injection. The cervical trachea was completely exposed by blunt dissection, a tracheal tube (2-mm internal diameter) was inserted into the trachea via a tracheotomy. The mice were then placed into the whole-body plethysmography chamber, and the tracheal tube was connected to the ventilator for mechanical ventilation with a tidal volume of 0.2 ml and a frequency of 140 breaths/min. After 5 min of equilibration on the ventilator, PBS and a series of increasing doses of Ach (3.125, 6.25, 12.5 and 25 mg/ml) were administered through the ventilator with an ultrasonic nebulizer. The data were collected through the sensor.

Serum, bronchoalveolar lavage fluid (BALF) and lung tissue specimen preparation
-------------------------------------------------------------------------------

The mice were sacrificed, following which one side of the bronchus was ligated and the airway on other side was lavaged three times with 0.5 ml of normal saline; 80% of the input volume was recovered. BALF was centrifuged at 500 × g for 10 min at 4°C. The total number of cells in the BALF was counted with a hemocytometer, and the percentages of the inflammatory cells were determined by counting 400 cells in randomly selected areas of the slide under a light microscope. All counts were performed in a blinded manner and in a randomized order by the same observer at the end of the experiment. The BALF supernatants were stored at −80°C for ELISA assessment.

Following the collection of BALF, all mice underwent an abdominal surgical procedure in which the abdominal anatomy was carefully examined to identify and expose the inferior vena cava, from which 0.5--1 ml of venous blood was withdrawn into a sterile Eppendorf tube. Following standing for 1 h, the sample was centrifuged at 1,000 × g at 4°C for 10 min, and the supernatant was stored at −80°C for further analysis.

The non-lavaged side of the lungs was harvested, the lower lobe was isolated, and fixed in 0.1 mmol/l paraformaldehyde, and was made into 4-*µ*m thick paraffin-embedded tissue sections for histopathological analysis via immunohistochemistry. The upper and middle lobes were stored at −80°C in a refrigerator for reverse transcription-qPCR (RT-qPCR) and western blot analyses.

ELISA for TGFβ1 in serum and BALF
---------------------------------

The concentrations of TGFβ1 in the serum and BALF were measured with an ELISA kit according to the manufacturer\'s protocol. A microplate reader was used to detect the optical density (OD) for the ELISA. TGFβ1 levels were determined by the OD values.

Lung tissue histopathology
--------------------------

The paraffin-embedded sections were stained with hematoxylin and eosin (H&E) to observe changes in airway inflammation and airway remodeling. Periodic acid-Schiff (PAS) staining was performed to evaluate airway goblet cell hyperplasia and mucus production. The stained sections were mounted on slides and examined under a light microscope (Olympus BX50, Olympus, Tokyo, Japan). Images were captured with a Nikon DS-Ri2 digital camera.

Epithelial thickness, the area between the luminal cell membrane and the basement membrane, was measured at four sites in five different medium-sized bronchi per slide using Image Pro Plus 6.0 image analysis software (Media Cybernetics, Inc., Rockville, MD, USA). All the measurements are provided as the average epithelial thickness per group.

Immunohistochemical analysis of the expression of E-cadherin and vimentin in lung tissues
-----------------------------------------------------------------------------------------

The sections of lung tissues were deparaffinized in xylene and rehydrated in graduated ethanol solutions. Following microwave-based antigen retrieval with citric acid pretreatment, the sections were incubated in 1% hydrogen peroxide for 15 min to block endogenous peroxidase. Subsequently, the specimens were incubated with a mouse polyclonal antibody to E-cadherin (1:200) or a rabbit polyclonal antibody to vimentin (1:200) at 4°C overnight, respectively. The sections were then incubated with anti-mouse (cat. no. CW01025) or anti-rabbit (cat. no. CW01035) horseradish peroxidase (HRP)-conjugated secondary antibody (1:100; Beijing Com Win Biotech Co., Ltd.) for 30 min at room temperature, followed by staining with DAB ([@b22-ijmm-42-04-1998]). For the negative control, the primary antibody was replaced with PBS. The sections were observed under a light microscope (magnification, ×400). E-cadherin was mainly expressed in the cell membrane and cytoplasm, whereas vimentin was mainly expressed in the cytoplasm. The brown staining of a cell membrane or cytoplasm is a positive signal in protein immunohistochemistry. The mean integrated OD (IOD) was then detected using the Image Pro Plus 6.0 image analysis system for all the sections. The IOD value represented the expression of each protein. The mean IOD values of each group were compared.

RT-qPCR analysis of E-cadherin and vimentin expression
------------------------------------------------------

Total RNA was extracted from the lung tissues using TRIzol. The mRNA was then reverse transcribed using a reverse transcription kit, according to the manufacturer\'s protocol. The reaction system was made up to 20 *µ*l with RNAse free water and contained 2.5 mM MgCl~2~ (4 *µ*l), reverse transcription 10X buffer (2 *µ*l), 0.5 mg/ml primers (1 *µ*l), dNTP mix (2 *µ*l) and AMV reverse transcriptase (0.7 *µ*l). The RT reaction occurred at 42°C for 1 h and was subsequently inactivated at 95°C for 5 min. A qPCR kit was used to amplify the resulting cDNAs, and fluorescence was detected with an 7500 PCR detection system (Applied Biosystems; Thermo Fisher Scientific, Inc.). The PCR reaction system was made up to 20 *µ*l with RNAse free water and contained 2X TransStart Green qPCR Super MIX UDG (10 *µ*l), 10 *µ*M forward primer (0.4 *µ*l), 10 *µ*M reverse primer (0.4 *µ*l), 50X passive reference dye (0.4 *µ*l) and cDNA (1 *µ*l). The thermocycling conditions were as follows: 50°C for 2 min, 94°C for 10 min, followed by 40--45 cycles of 94°C for 5 sec and 60°C for 30 sec. GADPH was used as an internal control. The PCR products were subjected to melting curve analysis to ensure that a single amplification product was produced. The relative expression levels of E-cadherin and vimentin were calculated using the quantification cycle (2^−ΔΔCq^) method ([@b23-ijmm-42-04-1998]). The sequences of primers used for RT-qPCR analysis are listed in [Table I](#tI-ijmm-42-04-1998){ref-type="table"}.

Western blot analysis of E-cadherin and vimentin expression
-----------------------------------------------------------

Total protein was extracted from lung tissues using RIPA lysis buffer. Protein concentration was determined with a BCA protein assay, following which the proteins (50 *µ*g/lane) were separated on 15% SDS-PAGE gels and transferred onto PVDF membranes. The membranes were blocked with 5% non-fat milk for 1 h at room temperature and then incubated with anti-E-cadherin (1:1,000) and anti-vimentin (1:1,000) antibodies overnight at 4°C. The β-actin antibody (1:2,000) was used as an internal control. Following three washes, the membranes were probed with HRP-conjugated secondary antibodies (1:3,000 in blocking buffer) at room temperature for 2 h and visualized with ECL reagent. The relative expression levels of E-cadherin and vimentin were quantified using Image lab Version 6.0 software (Bio-Rad Laboratories, Inc.) and were normalized to levels of β-actin. The normalized level of expression in the control group was set to 1.00, and the normalized expression in the OVA and OVA + BMS-345541 groups is expressed relative to the control.

Statistical analysis
--------------------

All data were processed using SPSS 19.0 (IBM SPSS, Armonk, NY, USA), and all quantitative data are presented as the mean ± standard deviation (n=8 mice/sample per group). The data were compared using a single-factor analysis of variance following variance determination. Comparisons among multiple groups were assessed using the Least Significant Difference method. If the variance was not homogeneous, Tamhane\'s multiple comparison procedure was used to assess comparisons among multiple groups. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

Effect of BMS-345541 on OVA-induced symptoms
--------------------------------------------

During OVA challenge, the OVA-group mice showed a variety of asthma-related symptoms, including dysphoria, shortness of breath and irregular breath rhythm, cyanosis, coughing, nose scratching and ear grasping, shrinking forelimb lift, and decreased activity. However, following treatment with BMS-345541, the asthmatic symptoms in the OVA + BMS-345541 group were significantly reduced, compared with those in the OVA and OVA + DMSO groups. The control group mice exhibited no asthma attack or allergic symptoms.

Effect of BMS-345541 on airway responsiveness
---------------------------------------------

To evaluate the effect of BMS-345541 on AHR in response to Ach, the RL was measured in an invasive whole-body plethysmography chamber in anesthetized mice. No significant differences in baseline airway resistance were observed among the four groups. The administration of Ach at doses increasing progressively between 3.125 and 25 mg/ml led to markedly increased RL values in the OVA group compared with those in the control group (P\<0.001). However, compared with the OVA group, treatment with BMS-345541 resulted in a significant decrease in RL (P\<0.01). The change in RL in the OVA + DMSO group was close to that in the OVA group ([Fig. 2](#f2-ijmm-42-04-1998){ref-type="fig"}, [Table II](#tII-ijmm-42-04-1998){ref-type="table"}).

Effect of BMS-345541 on airway inflammation and remodeling
----------------------------------------------------------

Airway inflammation is characterized by the infiltration of inflammatory cells. The degree of airway inflammation was evaluated via histopathological analysis of lung lesions (H&E staining; [Fig. 3A--D](#f3-ijmm-42-04-1998){ref-type="fig"}), and by total cell counts and inflammatory cell percentage, including eosinophils, lymphocytes, neutrophils and macrophages, in the BALF. The mice in the OVA and OVA + DMSO groups exhibited an influx of inflammatory cells around the bronchi and bronchioles along with submucosal edema, as shown in [Fig. 3B and C](#f3-ijmm-42-04-1998){ref-type="fig"}. The total cell numbers and the percentages of eosinophil and lymphocytes were higher in the OVA-induced mice than those in the control group. By contrast, the BMS-345541 treatment group exhibited less inflammatory cell infiltration and edema.

Goblet cell hyperplasia is one of the critical pathophysiologic changes in the airway remodeling of asthma ([@b24-ijmm-42-04-1998]). PAS staining was used to evaluate airway global cell hyperplasia and mucus production ([Fig. 3E--H](#f3-ijmm-42-04-1998){ref-type="fig"}). The lung tissue from the OVA mice ([Fig. 3F](#f3-ijmm-42-04-1998){ref-type="fig"}) exhibited airway remodeling compared with that in the control group ([Fig. 3E](#f3-ijmm-42-04-1998){ref-type="fig"}), including the enlargement of airway smooth muscle, basement membrane thickening, goblet cell hyperplasia, mucus hypersecretion, and epithelium damage. The OVA + DMSO group ([Fig. 3G](#f3-ijmm-42-04-1998){ref-type="fig"}) exhibited similar changes. However, the development of airway remodeling was significantly attenuated by the administration of BMS-345541. Despite inflammatory changes, the mice in the OVA + BMS-345541 group showed only marginal bronchial wall thickening, airway stenosis and epithelial damage ([Fig. 3H](#f3-ijmm-42-04-1998){ref-type="fig"}).

Following BMS-345541 treatment, the increased cell counts and eosinophil percentages were markedly decreased compared with the corresponding values in the OVA mice (P\<0.05). There was no change between the OVA and OVA + DMSO groups ([Fig. 4](#f4-ijmm-42-04-1998){ref-type="fig"}, [Table III](#tIII-ijmm-42-04-1998){ref-type="table"}).

The epithelial thicknesses were examined to assess the features of airway remodeling. A quantitative assessment of epithelial thickness demonstrated significant increases in the OVA group (28.02±8.09 *µ*m) and the OVA + DMSO group (27.80±5.93 *µ*m). There was a significant difference between the OVA and the control groups (P\<0.001). However, the epithelial thickness was markedly alleviated by the administration of BMS-345541 (10.71±4.18 *µ*m). There was also a significant difference between the OVA + BMS-345541 and the OVA groups (P\<0.001) ([Fig. 5](#f5-ijmm-42-04-1998){ref-type="fig"}, [Table IV](#tIV-ijmm-42-04-1998){ref-type="table"}).

Effect of BMS-345541 on the concentrations of TGFβ1 in serum and BALF
---------------------------------------------------------------------

TGFβ1 is an important cytokine involved in airway remodeling, and is important in EMT ([@b25-ijmm-42-04-1998]). TGFβ1 mediates tissue inflammation in asthma ([@b26-ijmm-42-04-1998]). Concentrations of TGFβ1 in the serum and BALF were detected by ELISA, and it was found that the OVA group had markedly elevated levels of serum and BALF TGFβ1, compared with the control group. No difference between the OVA and OVA + DMSO groups was found. However, unlike in the OVA + DMSO group, the concentrations of TGFβ1 in the BMS-345541-treated OVA group were significantly decreased compared with those in the OVA group ([Fig. 6](#f6-ijmm-42-04-1998){ref-type="fig"}, [Table V](#tV-ijmm-42-04-1998){ref-type="table"}).

Effect of BMS-345541 on the expression of E-cadherin and vimentin as assessed by immunohistochemistry, RT-qPCR and western blot analyses
----------------------------------------------------------------------------------------------------------------------------------------

The epithelial marker E-cadherin and the mesenchymal marker vimentin are important markers of EMT. The expression levels of E-cadherin and vimentin were estimated by immunohistochemical image analysis. The mRNA and protein levels of E-cadherin and vimentin were determined by RT-qPCR and western blot analyses. As shown in [Fig. 7A--G](#f7-ijmm-42-04-1998){ref-type="fig"}, the results of the immunohistochemistry indicated a significant decrease in the expression of E-cadherin and an increase in the expression of vimentin in the epithelium of the OVA-induced mice ([Fig. 7B and G](#f7-ijmm-42-04-1998){ref-type="fig"}). Following the daily administration of BMS-345541, the expression of E-cadherin was increased, whereas the expression of vimentin was decreased, as shown in [Fig. 7D and I](#f7-ijmm-42-04-1998){ref-type="fig"}. No E-cadherin or vimentin was identified in the negative controls ([Fig. 7E and J](#f7-ijmm-42-04-1998){ref-type="fig"}).

As shown in [Fig. 8](#f8-ijmm-42-04-1998){ref-type="fig"} and [Table VI](#tVI-ijmm-42-04-1998){ref-type="table"}, the expression of EMT markers was further investigated by IOD measurement. It was found that the IOD value of vimentin was higher in the OVA group and the OVA + DMSO group, whereas the IOD value in the OVA + BMS-345541 group decreased significantly. By contrast, it was found that the E-cadherin IOD values were decreased in the OVA and OVA + DMSO groups, and increased in the OVA + BMS-345541 group following BMS-345541 administration. There were significant differences between the OVA and the control groups (P\<0.01), and the OVA and OVA + BMS-345541 groups (P\<0.05). No significant difference was observed between the OVA and the OVA + DMSO groups.

The mRNA and protein levels showed the same results, which were consistent with the immunohistochemical results. As shown in [Fig. 9A--D](#f9-ijmm-42-04-1998){ref-type="fig"} and [Table VII](#tVII-ijmm-42-04-1998){ref-type="table"}, the same results were observed for the expression of E-cadherin, which was down-regulated, and expression of vimentin, which was upregulated, in the OVA group mice. BMS-345541 supressed the expression of vimentin and promoted the expression of E-cadherin. These results indicated that BMS-345541 regulated the EMT process in mice with asthma, whereas DMSO did not have a similar effect.

Discussion
==========

Asthma is a chronic inflammatory disorder, and the predisposing factors and pathogenesis of asthma are complicated. In the present study, mice were challenged with OVA to produce an allergy model of asthma. Normal control and DMSO therapeutic control groups were set up in this experiment. On the basis of this mouse asthma model, EMT characteristics, airway inflammation, airway remodeling, and airway reactivity were investigated in the asthmatic mice. Additionally, the treatment effects of BMS-345541 on OVA-induced asthmatic mice were observed, and the molecular regulation and intervention mechanisms of this treatment in the airway remodeling of asthma were examined.

In the experiment, mice in the OVA group exhibited a variety of asthma-related symptoms. AHR is an important characteristic feature of asthma. Several factors contribute to its development. The administration of Ach at progressively increasing doses led to a marked increase in RL in the OVA asthma group. These results showed that the OVA-induced asthmatic mice exhibited AHR.

Airway inflammation is central to asthma pathophysiology and considered to be the key trigger of AHR. The development of airway inflammation involves a large number of inflammatory cells, particularly eosinophils, infiltrating the lung tissue, gathering around the bronchus, and periodically infiltrating into the BALF. Eosinophils are required for the occurrence of airway remodeling. The hypersecretion of airway mucus, produced and secreted from goblet cells, is an important cause of airway obstruction, asthma deterioration and fatal asthma ([@b27-ijmm-42-04-1998]). In the present study, the OVA group exhibited significant inflammatory cell infiltration around the blood vessels and bronchi, submucosal edema, increased numbers of total cells, and an increased percentage of eosinophils in the BALF, compared with the control group. The lung tissue from mice in the OVA group exhibited airway remodeling, including enlargement of airway smooth muscle, basement membrane thickening, epithelial damage, subepithelial fibrosis, goblet cell hyperplasia, and mucus hypersecretion. All these observations suggested that the asthmatic signs of airway inflammation and airway remodeling were established successfully in the OVA-induced mouse model.

TGFβ has three isomers (TGFβ1, TGFβ2, and TGFβ3), which show a high degree of homology. Among them, TGFβ1 is important in biological functions. It remains controversial whether TGFβ1 has different roles in the differentiation, expression of contractile proteins, and mediation of the proliferation of airway cells ([@b28-ijmm-42-04-1998]). The mechanisms underlying the effects of TGFβ1 on asthma remain to be fully elucidated. There are various hypotheses regarding the role of TGFβ1 in asthma. The majority of studies have shown that TGFβ1 can trigger EMT ([@b29-ijmm-42-04-1998]) and that it is important in the onset of asthma and airway remodelling ([@b25-ijmm-42-04-1998]). TGFβ1 is a remodeling related mediator; additionally, the increased secretion of TGFβ1 induced by asthmatic chronic inflammation may result in EMT, which is one of the most important mechanisms of airway inflammation and airway remodeling in asthma ([@b7-ijmm-42-04-1998]). The present study detected TGFβ1 concentrations in mouse serum and BALF samples by ELISA. The mice in the OVA group exhibited increased expression of TGFβ1 in serum and BALF. These findings indicated that TGFβ1 was associated with the inflammation and airway hyperactivity in asthma.

The E-cadherin and vimentin proteins are considered to be critical biomarkers of EMT ([@b30-ijmm-42-04-1998]). The loss of E-cadherin, a cell-cell adhesion protein, disrupts epithelial barrier function and causes the bronchial epithelium to lose its structural stability and polarity, which is necessary for bronchial epithelial cell migration. The increased expression of vimentin, an intermediate filament protein, alters the cytoskeletal protein composition and thus drives the transformation of epithelial-derived cubic-shaped cells into spindle-shaped fibre-like cells, which subsequently gain the ability to migrate ([@b31-ijmm-42-04-1998]). A previous study found that the expression of E-cadherin decreased and that of vimentin increased in airway epithelial cells from asthmatic mice exposed to dust mites ([@b32-ijmm-42-04-1998]). Furthermore, lower expression of E-cadherin in patients with asthma has been associated with more severe loss of airway barrier function, which promotes the development of airway remodelling ([@b33-ijmm-42-04-1998]). In the present study, the expression of E-cadherin was downregulated and the expression of vimentin was upregulated in mice in the OVA group. These results further confirmed the role of TGFβ1-induced EMT on airway remodeling, and suggested that it promotes airway inflammation and is involved in the pathogenesis of asthma.

The NF-κB signaling pathway is central in the pathogenesis of airway inflammation in asthma ([@b34-ijmm-42-04-1998]). NF-κB is already under consideration as a promising novel target for the treatment of asthma. Inhibition of the NF-κB pathway by inhibitors has been shown to attenuate allergic airway inflammation in mice ([@b35-ijmm-42-04-1998]). IKKβ, the target of BMS-345541, is a key positive regulator of NF-κB. The inhibition of IKKβ inhibits the activation of NF-κB. BMS-345541 is a highly selective inhibitor of IκB kinase, which binds at an allosteric site of the enzyme and inhibits NF-κB-dependent transcription in mice ([@b36-ijmm-42-04-1998]). BMS-345541 does not bind to the ATP binding site, and oral BMS-345541 is well tolerated by mice. A previous study found that mice administered with a prophylactic dose of BMS-345541 exhibited no toxicological changes, even at the efficacious dose of 100 mg/kg ([@b15-ijmm-42-04-1998]). Therefore, BMS-345541 is considered safe and particularly well suited to the investigation of the use of IKK inhibitors in murine models of inflammation. BMS-345541 remains at micromolar serum drug levels for several hours following an oral dose and is biochemically active in mice ([@b37-ijmm-42-04-1998]). Treatment with varying doses of BMS-345541 (10--100 mg/kg, p.o.) can inhibit inflammation in mice to different degrees, with a high dosage (100 mg/kg) of BMS-345541 showing therapeutic effects comparable with the effects of glucocorticoid treatments ([@b15-ijmm-42-04-1998]).

In the preliminary experiments of the present study, normal female BALB/c mice (aged 6--8 weeks, weighing 25±3 g) were fed with BMS-345541 or DMSO for 7 days. None of the mice showed abnormal behavior or death during this process. In addition, lung samples from the mice were stained with H&E to observe their pathological features, and no changes were found from the observations in the control mice. Therefore, BMS-345541 and DMSO were considered safe and non-toxic. This finding was similar to the results of previous studies ([@b15-ijmm-42-04-1998],[@b38-ijmm-42-04-1998]).

Subsequent experiments performed in the present study aimed to examine the therapeutic effect of BMS-345541, in which 50 mg/kg BMS-345541 was used to treat OVA-induced asthma in mice, with DMSO used as the therapeutic control vehicle simultaneously. It was found that the asthma symptoms were relieved by BMS-345541 treatment, with RL values significantly decreased, compared with the values in the OVA and OVA + DMSO groups. In addition, following BMS-345541 treatment, there were a series of other changes, whereas DMSO had no similar effects. In the OVA + BMS-345541 group, histopathological changes of lung lesions, including epithelial thickening, bronchospasm, inflammatory cell infiltration, and mucus secretion, were significantly reduced. The BMS-345541 treatment group exhibited less inflammatory cell infiltration, and the cell count and eosinophil percentage were markedly decreased. The levels of TGFβ1 in the BALF and serum were also decreased. BMS-345541 treatment was accompanied by the upregulated expression of the epithelial marker E-cadherin and downregulated expression of the mesenchymal marker vimentin, which was verified by immunohistochemistry, RT-qPCR and western blot analyses. These changes in EMT marker protein expression were inhibited by BMS-345541 treatment. Therefore, these results further confirmed that BMS-345541 inhibited the production of TGFβ1 and ameliorated airway hyperresponsiveness via the inhibition of IKKβ. BMS-345541 treatment protected from OVA-induced allergic airway inflammation and attenuated EMT in airway remodeling in asthmatic mice.

The present study had a number of limitations, including the fact that there was no investigation of the effect of BMS-345541 on lung immune cells, including CD3, CD4, CD8, regulatory T, T helper 17, and B cells. There was also no investigation of changes resulting from BMS-345541 to major secretory mucins, including MUC5AC and MUC5B, nor were changes to major extracellular matrix components investigated. There was also no investigation of fundamental inflammatory mediators in the pathogenesis of bronchial asthma, including IgE, interleukin (IL)-4, IL-5, IL-5 receptor, and IL-13. In the future, these limitations are to be addressed. Similar to previous studies, as bronchial specimens are not easily acquired in mice, the lungs of the mice were selected and harvested for histopathology to obtain supernatants following lung homogenization and to obtain nuclear and protein extracts to detect the mRNA and protein levels of E-cadherin and vimentin. Future investigations aim to obtain bronchial specimens for confirmation of the results. In addition, only the preliminary experiments included BMS-345541 alone and DMSO alone control groups, which were not included in later experiments and presents another limitation of the study. Further improvements are required in the future.

In conclusion, an allergic asthmatic mouse model can be established successfully by OVA sensitization and challenge. Asthmatic mice in this model have the typical airway inflammation, airway hyperresponsiveness and airway remodeling observed in asthma. Airway remodeling is observed in OVA-treated asthmatic mice, in addition to evidence of EMT. The increased secretion of TGFβ1 by asthmatic inflammation may result in EMT. TGFβ1, NF-κB and EMT are important for asthma. The IKKβ inhibitor, BMS-345541, had a therapeutic effect on asthma airway inflammation and airway remodeling. The therapeutic mechanism may be achieved through decreasing the expression of TGFβ1, inhibiting the activation of NF-κB and reducing EMT. The results of the present study provide an experimental basis for the potential use of IKKβ inhibitors as therapeutics in the clinical treatment of asthma. IKKβ inhibitors may be promising candidates for pharmacologic agents to use in future human asthma therapy.
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![Experimental design for the OVA-induced asthma model. Mice were sensitized with intraperitoneal injections of 10 *µ*g of OVA emulsified in aluminium hydroxide in a total volume of 0.5 ml on days 0, 7 and 14, followed by seven consecutive challenges each day by exposure to OVA aerosol for 30 min. Prior to daily OVA nebulization challenge, BMS-345541 or DMSO were administered in the BMS-345541- or DMSO-treated groups, respectively. The control mice were treated with PBS for the sensitization and stimulation. Mice were sacrificed 24 h following the final challenge. BALF samples were collected and the lungs were dissected for analysis. OVA, ovalbumin; BALF, bronchoalveolar lavage fluid; PBS, phosphate-buffered saline; DMSO, dimethyl sulfoxide.](IJMM-42-04-1998-g00){#f1-ijmm-42-04-1998}

![BMS-345541 suppresses airway hyperactivity in OVA-sensitized mice. Data are presented as the mean ± standard deviation (n=8 per group). ^\#^P\<0.001, OVA group, compared with the control group; ^\*^P\<0.01 and \*\*P\<0.001, OVA + BMS-345541 group compared with the OVA group. RL, lung resistance; OVA, ovalbumin; DMSO, dimethyl sulfoxide.](IJMM-42-04-1998-g01){#f2-ijmm-42-04-1998}

![BMS-345541 attenuates airway inflammation, airway goblet cell hyperplasia and mucus production in OVA-induced asthmatic mice. Hematoxylin and eosin staining in (A) control, (B) OVA, (C) OVA + DMSO and (D) OVA + BMS-345541. Periodic acid-Schiff staining of (E) control, (F) OVA, (G) OVA + DMSO and (H) OVA + BMS-345541. Original magnification, ×200. OVA, ovalbumin; DMSO, dimethyl sulfoxide.](IJMM-42-04-1998-g02){#f3-ijmm-42-04-1998}

![BMS-345541 inhibits inflammatory cell accumulation in the BALF in a mouse model of asthma. In the OVA + BMS-345541 group, the cell counts and percentages of eosinophils in the BALF were decreased. The data are presented as the mean ± standard deviation (n=8 per group). ^\#^P\<0.05 and ^\#\#^P\<0.01, OVA group compared with the control group; ^\*^P\<0.05 and ^\*\*^P\<0.01, OVA + BMS-345541 group compared with the OVA group. OVA, ovalbumin; BALF, bronchoalveolar lavage fluid; DMSO, dimethyl sulfoxide.](IJMM-42-04-1998-g03){#f4-ijmm-42-04-1998}

![BMS-345541 attenuates airway remodeling in a mouse model of asthma. Epithelial thickness was measured by Image Pro Plus 6.0 image-analysis software. Average measurements were obtained. The data are presented as the mean ± standard deviation (n=8 per group). ^\#^P\<0.001, OVA group compared with the control group; ^\*^P\<0.001, OVA + BMS-345541 group compared with the OVA group. OVA, ovalbumin; DMSO, dimethyl sulfoxide.](IJMM-42-04-1998-g04){#f5-ijmm-42-04-1998}

![BMS-345541 decreases the levels of TGFβ1 in the serum and BALF in a mouse model of asthma, as analyzed by enzyme-linked immunosorbent assay. The values are expressed as the mean ± standard deviation (n=8 per group). ^\#^P\<0.01, OVA group compared with the control group; ^\*^P\<0.05 and ^\*\*^P\<0.01, OVA + BMS-345541 group compared with the OVA group. OVA, ovalbumin; BALF, bronchoalveolar lavage fluid; TGFβ1, transforming growth factor β1; DMSO, dimethyl sulfoxide.](IJMM-42-04-1998-g05){#f6-ijmm-42-04-1998}

![BMS-345541 inhibits epithelial-mesenchymal transition in asthma. Immunohistochemistry images (magnification, ×400) of E-cadherin in the (A) control, (B) OVA, (C) OVA + DMSO, and (D) OVA + BMS-345541 groups; (E) negative control of E-cadherin. Images of vimentin in the (F) control, (G) OVA, (H) OVA + DMSO, (I) OVA + BMS-345541; (J) negative control of vimentin. Staining in pulmonary tissue sections is shown for all groups. OVA, ovalbumin; DMSO, dimethyl sulfoxide.](IJMM-42-04-1998-g06){#f7-ijmm-42-04-1998}

![Mean IOD detection using an image-analysis system in immunohistochemistry sections. Compared with the values in the OVA-induced asthmatic mice, the E-cadherin expression IOD was increased, whereas the vimentin expression IOD was decreased in the BMS-345541-treated group. The values are expressed as the mean ± standard deviation (n=8 per group). ^\#^P\<0.01, OVA group compared with the control group; ^\*^P\<0.05, OVA + BMS-345541 group compared with the OVA group. IOD, integrated optical density; OVA, ovalbumin; DMSO, dimethyl sulfoxide.](IJMM-42-04-1998-g07){#f8-ijmm-42-04-1998}

![BMS-345541 inhibits epithelial-mesenchymal transition in asthma. mRNA levels of E-cadherin and vimentin in mouse lung tissues were measured by (A) reverse transcription-quantitative polymerase chain reaction analysis. (B) Protein levels were measured by western blot analysis for (C) E-cadherin and (D) vimentin. Data are presented as the mean ± standard deviation (n=8 per group). ^\#^P\<0.01 and ^\#\#^P\<0.001, OVA group compared with the control group; ^\*^P\<0.05 and ^\*\*^P\<0.01, OVA + BMS-345541 group compared with the OVA group. OVA, ovalbumin; DMSO, dimethyl sulfoxide.](IJMM-42-04-1998-g08){#f9-ijmm-42-04-1998}

###### 

Primers and sequences.

  Name                      Sequence (5′-3′)          Fragment length (bp)
  ------------------------- ------------------------- ----------------------
  E-cadherin                F: AAAAGAAGGCTGTCCTTGGC   106
  R: GAGGTCTACACCTTCCCGGT                             
  Vimentin                  F: TCCACTTTCCGTTCAAGGTC     91
  R: AGAGAGAGGAAGCCGAAAGC                             
  GAPDH                     F: ATGGAGGGGAATACAGCCC    
  R: TTCTTTGCAGCTCCTTCGTT   149                       

F, forward; R, reverse.

###### 

Lung resistance (cm H~2~O.ml^−1^.sec^−1^).

  Group              N   Baseline    3.125                                                      6.25                                                       12.5                                                        25
  ------------------ --- ----------- ---------------------------------------------------------- ---------------------------------------------------------- ----------------------------------------------------------- -----------------------------------------------------------
  Control            8   1.49±0.36   2.20±0.55                                                  2.71±0.74                                                  3.00±0.71                                                   3.81±0.48
  OVA                8   1.49±0.36   3.11±0.34[a](#tfn3-ijmm-42-04-1998){ref-type="table-fn"}   7.66±0.53[a](#tfn3-ijmm-42-04-1998){ref-type="table-fn"}   11.09±1.28[a](#tfn3-ijmm-42-04-1998){ref-type="table-fn"}   19.79±1.48[a](#tfn3-ijmm-42-04-1998){ref-type="table-fn"}
  OVA + DMSO         8   1.49±0.36   2.91±0.27                                                  7.59±0.50                                                  11.11±1.41                                                  19.31±1.04
  OVA + BMS-345541   8   1.49±0.36   2.52±0.31[b](#tfn4-ijmm-42-04-1998){ref-type="table-fn"}   3.38±0.49[c](#tfn5-ijmm-42-04-1998){ref-type="table-fn"}   4.59±0.72[c](#tfn5-ijmm-42-04-1998){ref-type="table-fn"}    6.20±1.04[c](#tfn5-ijmm-42-04-1998){ref-type="table-fn"}
  F-value                \<0.001     9.037                                                      172.304                                                    125.589                                                     499.166
  P-value                1.00        \<0.001                                                    \<0.001                                                    \<0.001                                                     \<0.001

Data are shown as the mean ± standard deviation.

P\<0.01, compared with the control group;

P\<0.01 and

P\<0.001, compared with the OVA group. OVA, ovalbumin; DMSO, dimethyl sulfoxide.

###### 

Cell counts and percentages of inflammatory cells in the BALF.

  Group              N   Total cells (10^6^/l)                                      Macrophages (%)   Eosinophil (%)                                              Lymphocytes (%)                                             Neutrophils (%)
  ------------------ --- ---------------------------------------------------------- ----------------- ----------------------------------------------------------- ----------------------------------------------------------- -----------------
  Control            8   0.33±0.28                                                  41.56±4.44        1.94±0.90                                                   32.19±5.80                                                  11.06±3.73
  OVA                8   2.92±1.68[a](#tfn7-ijmm-42-04-1998){ref-type="table-fn"}   28.19±10.50       15.08±3.26[b](#tfn8-ijmm-42-04-1998){ref-type="table-fn"}   39.31±3.39[a](#tfn7-ijmm-42-04-1998){ref-type="table-fn"}   12.94±3.39
  OVA + DMSO         8   2.89±1.48                                                  38.31±9.86        16.20±3.18                                                  39.94±5.41                                                  10.00±3.30
  OVA + BMS-345541   8   1.72±1.63[c](#tfn9-ijmm-42-04-1998){ref-type="table-fn"}   41.25±12.37       3.81±1.25[d](#tfn10-ijmm-42-04-1998){ref-type="table-fn"}   36.81±2.80                                                  12.00±3.97
  F-value                11.354                                                     1.803             80.080                                                      7.013                                                       0.976
  P-value                \<0.001                                                    0.169             \<0.001                                                     0.001                                                       0.418

Data are shown as the mean ± standard deviation.

P\<0.05 and

P\<0.01, compared with the control group;

P\<0.05 and

P\<0.01, compared with the OVA group. OVA, ovalbumin; DMSO, dimethyl sulfoxide.

###### 

Epithelial thickness.

  Group              N   Epithelial thickness (*µ*m)
  ------------------ --- ------------------------------------------------------------
  Control            8   8.85±3.15
  OVA                8   28.02±8.09[a](#tfn12-ijmm-42-04-1998){ref-type="table-fn"}
  OVA + DMSO         8   27.81±5.93
  OVA + BMS-345541   8   10.71±4.18[b](#tfn13-ijmm-42-04-1998){ref-type="table-fn"}
  F-value                27.545
  P-value                \<0.001

Data are shown as the mean ± standard deviation.

P\<0.001, compared with the control group;

P\<0.001, compared with the OVA group. OVA, ovalbumin; DMSO, dimethyl sulfoxide.

###### 

TGFβ1 concentration in serum and BALF.

  Group              N   Serum (pg/ml)                                                 BALF (pg/ml)
  ------------------ --- ------------------------------------------------------------- -------------------------------------------------------------
  Control            8   31.53±14.41                                                   20.98±13.29
  OVA                8   84.41±38.18[a](#tfn15-ijmm-42-04-1998){ref-type="table-fn"}   44.36±10.98[a](#tfn15-ijmm-42-04-1998){ref-type="table-fn"}
  OVA + DMSO         8   89.63±28.62                                                   46.58±16.27
  OVA + BMS-345541   8   42.04±28.38[c](#tfn17-ijmm-42-04-1998){ref-type="table-fn"}   25.45±14.15[b](#tfn16-ijmm-42-04-1998){ref-type="table-fn"}
  F-value                8.405                                                         7.109
  P-value                \<0.001                                                       0.001

Data are shown as the mean ± standard deviation.

P\<0.01, compared with the control group;

P\<0.05 and

P\<0.01, compared with the OVA group. BALF, bronchoalveolar lavage fluid; OVA, ovalbumin; DMSO, dimethyl sulfoxide.

###### 

IOD of E-cadherin and vimentin expression.

  Group              N   E-cadherin                                                  Vimentin
  ------------------ --- ----------------------------------------------------------- -----------------------------------------------------------
  Control            8   0.34±0.28                                                   0.08±0.06
  OVA                8   0.05±0.04[a](#tfn19-ijmm-42-04-1998){ref-type="table-fn"}   0.43±0.33[a](#tfn19-ijmm-42-04-1998){ref-type="table-fn"}
  OVA + DMSO         8   0.05±0.05                                                   0.40±0.23
  OVA + BMS-345541   8   0.22±0.07[b](#tfn20-ijmm-42-04-1998){ref-type="table-fn"}   0.17±0.04[b](#tfn20-ijmm-42-04-1998){ref-type="table-fn"}
  F-value                7.164                                                       5.716
  P-value                0.001                                                       0.003

Data are shown as the mean ± standard deviation.

P\<0.01, compared with the control group;

P\<0.01, compared with the OVA group. OVA, ovalbumin; DMSO, dimethyl sulfoxide.

###### 

mRNA and protein expression levels of E-cadherin and vimentin.

  Group              N   E-cadherin                                                  Vimentin                                                                                                                
  ------------------ --- ----------------------------------------------------------- ----------------------------------------------------------- ----------------------------------------------------------- -----------------------------------------------------------
  Control            8   1.03±0.16                                                   1.00±0.00                                                   1.02±0.10                                                   1.00±0.00
  OVA                8   0.38±0.33[b](#tfn23-ijmm-42-04-1998){ref-type="table-fn"}   0.69±0.24[a](#tfn22-ijmm-42-04-1998){ref-type="table-fn"}   3.10±2.14[a](#tfn22-ijmm-42-04-1998){ref-type="table-fn"}   3.48±2.02[a](#tfn22-ijmm-42-04-1998){ref-type="table-fn"}
  OVA + DMSO         8   0.36±0.33                                                   0.66±0.22                                                   3.49±1.96                                                   3.62±2.09
  OVA + BMS-345541   8   0.89±0.35[d](#tfn25-ijmm-42-04-1998){ref-type="table-fn"}   0.94±0.16[c](#tfn24-ijmm-42-04-1998){ref-type="table-fn"}   1.00±0.28[d](#tfn25-ijmm-42-04-1998){ref-type="table-fn"}   1.05±0.78[d](#tfn25-ijmm-42-04-1998){ref-type="table-fn"}
  F-value                10.370                                                      7.805                                                       6.670                                                       7.501
  P-value                \<0.001                                                     0.001                                                       0.002                                                       0.001

Data are shown as the mean ± standard deviation.

P\<0.01 and

P\<0.001, compared with the control group;

P\<0.05 and

P\<0.01, compared with the OVA group. OVA, ovalbumin; DMSO, dimethyl sulfoxide.
